StratCorp Limited is an investment holding company based in South Africa, with wholly-owned subsidiaries involved in asset management, asset finance, health and lifestyle products and property development. Subsidiaries include Virtus and WealthNet (financial products), I-Cura (health products), general finance (StratFin) and StratCorp Properties.

The group’s history stems back to 2000, and StratCorp shares are today listed on the AltX of the Johannesburg Stock Exchange (JSE) with a market cap of R6.15 million. The company’s client base is predominantly LSM 4-7 consumers from previously disadvantaged backgrounds.

The company has experienced huge strife in recent years, struggling to attract investors to buy StratCorp shares due to lawsuits and financial troubles. This has resulted in a plunging StratCorp share price.

Significant doubt has arisen over whether StratCorp will remain a going concern, with StratCorp share price languishing at 1 cents on the JSE.

Much of the company’s troubles have been caused by Virtus, which claims to give investors access to a unique empowerment investment opportunity allowing them to buy shares in an investment company which invests in JSE-listed companies and other investment instruments. The company has a controversial network marketing business model which involves clients distributing products to other potential clients, and this has caught the attention of the Financial Services Board and resulted in lawsuits. Virtus recently had its operating license taken away, with the group’s directorship now seeking ways to keep the business afloat.

StratCorp further experienced declining client bases as a result of regulatory changes, increased legal costs and repayment of overdraft facilities. I-Cura’s client base continued to decrease, which the company is attempting to rectify through an increasing focus on telesales and moving the business away from a monthly subscription model.

Overall, the group reported poor performance for 2016, with revenue decreasing from R24.7 million to R17.2 million, and net losses coming in at R6.7 million. The group’s staff numbers remain constrained at around 40 people, and StratCorp has said it will be looking to boost its staff complement going forward. The forecast for the group is gloomy, as it does not have enough cash to pay off its liabilities for the foreseeable future. Attempts are being made to raise capital, but look unlikely to bear fruit.

StratCorp’s liabilities significantly outweigh its assets, it is at the sharp end of a number of legal disputes and it is difficult to see the group managing to chart a positive path going forward. With much more promising and credible stocks to buy on the JSE, StratCorp shares won’t be an option for the vast majority of investors. StratCorp share price is unlikely to strengthen on the live online JSE stocks chart.

Health Care

Biotech & Pharma

Specialty Pharma

We have made it simple to buy JSE listed firm shares online. The easiest way to buy StratCorp Group shares or stocks is to; start by submitting the ‘BUY THIS SHARE’ form. Next, one of our experienced and certified stock brokers will personally get in contact with you to discuss your custom stock request. Finally, a stock advisor will confirm the amount of shares you are looking to invest in StratCorp Group and assist you with the setup and management of your stock portfolio account.

1. Start by Filling in the BUY THIS SHARE form.
2. Insert your name, email, telephone number and monthly remuneration.
3. Then, Indicate the amount you are looking to invest in StratCorp Group.
4. Click the “ INVEST NOW” button
5. Once we have received your info, a dedicated stock advisor will personally call you back to discuss your personal share request.
6. Lastly, your newly appointed personal stock advisor will handle all account setups and reporting as stipulated by the financial services board of South Africa (FSB)

Buying JSE shares has never been this convenient and easy. #myfirstshare

View more JSE shares for sale – here.